319 related articles for article (PubMed ID: 17570740)
1. Relationship between matrix metalloproteinase 2 and lung cancer progression.
Guo CB; Wang S; Deng C; Zhang DL; Wang FL; Jin XQ
Mol Diagn Ther; 2007; 11(3):183-92. PubMed ID: 17570740
[TBL] [Abstract][Full Text] [Related]
2. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer.
Liu J; Ping W; Zu Y; Sun W
Int J Clin Exp Pathol; 2014; 7(9):6040-7. PubMed ID: 25337249
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer.
Suzuki M; Iizasa T; Fujisawa T; Baba M; Yamaguchi Y; Kimura H; Suzuki H
Invasion Metastasis; 1998-1999; 18(3):134-41. PubMed ID: 10474026
[TBL] [Abstract][Full Text] [Related]
4. PKCζ, MMP‑2 and MMP‑9 expression in lung adenocarcinoma and association with a metastatic phenotype.
Cai X; Zhu H; Li Y
Mol Med Rep; 2017 Dec; 16(6):8301-8306. PubMed ID: 28983601
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR.
Simi L; Andreani M; Davini F; Janni A; Pazzagli M; Serio M; Orlando C
Lung Cancer; 2004 Aug; 45(2):171-9. PubMed ID: 15246188
[TBL] [Abstract][Full Text] [Related]
6. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study.
Pietruszewska W; Bojanowska-Poźniak K; Kobos J
Otolaryngol Pol; 2016 Jun; 70(3):32-43. PubMed ID: 27386931
[TBL] [Abstract][Full Text] [Related]
8. Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma.
Kunz P; Sähr H; Lehner B; Fischer C; Seebach E; Fellenberg J
BMC Cancer; 2016 Mar; 16():223. PubMed ID: 26979530
[TBL] [Abstract][Full Text] [Related]
9. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas.
Yamamura T; Nakanishi K; Hiroi S; Kumaki F; Sato H; Aida S; Kawai T
Lung Cancer; 2002 Mar; 35(3):249-55. PubMed ID: 11844598
[TBL] [Abstract][Full Text] [Related]
10. Expression of MiR200a, miR93, metastasis-related gene RECK and MMP2/MMP9 in human cervical carcinoma--relationship with prognosis.
Wang L; Wang Q; Li HL; Han LY
Asian Pac J Cancer Prev; 2013; 14(3):2113-8. PubMed ID: 23679328
[TBL] [Abstract][Full Text] [Related]
11. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
12. [Correlations of S100A4 and MMP9 expressions to infiltration, metastasis and prognosis of non-small cell lung cancer].
Chen XL; Wang LC; Zhang WG; Chen XY; Sun ZM
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1254-8. PubMed ID: 18676277
[TBL] [Abstract][Full Text] [Related]
13. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
14. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY
Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression.
Zeng Q; Li S; Zhou Y; Ou W; Cai X; Zhang L; Huang W; Huang L; Wang Q
Cytokine; 2014 Jan; 65(1):24-32. PubMed ID: 24140068
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma.
Cho NH; Shim HS; Rha SY; Kang SH; Hong SH; Choi YD; Hong SJ; Cho SH
Eur Urol; 2003 Nov; 44(5):560-6. PubMed ID: 14572755
[TBL] [Abstract][Full Text] [Related]
17. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.
Pritchard SC; Nicolson MC; Lloret C; McKay JA; Ross VG; Kerr KM; Murray GI; McLeod HL
Oncol Rep; 2001; 8(2):421-4. PubMed ID: 11182067
[TBL] [Abstract][Full Text] [Related]
18. LATS2 as a poor prognostic marker regulates non-small cell lung cancer invasion by modulating MMPs expression.
Wu A; Li J; Wu K; Mo Y; Luo Y; Ye H; Mai Z; Guo K; Wang Y; Li S; Chen H; Luo W; Yang Z
Biomed Pharmacother; 2016 Aug; 82():290-7. PubMed ID: 27470365
[TBL] [Abstract][Full Text] [Related]
19. Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression.
Chang YC; Chan YC; Chang WM; Lin YF; Yang CJ; Su CY; Huang MS; Wu ATH; Hsiao M
Cancer Lett; 2017 Sep; 403():28-36. PubMed ID: 28610954
[TBL] [Abstract][Full Text] [Related]
20. Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis.
Jiang H; Li H
BMC Cancer; 2021 Feb; 21(1):149. PubMed ID: 33568081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]